Key takeaways
Dovato (dolutegravir/lamivudine) and Juluca (dolutegravir/rilpivirine) are both HIV treatments, but they have some key differences. Dovato is used as a first-choice treatment for adults starting HIV medications, while Juluca is meant for people who are already well-controlled on their current HIV regimen and want to switch. Dovato combines an integrase inhibitor (dolutegravir) and a nucleoside reverse transcriptase inhibitor (lamivudine), whereas Juluca combines the same integrase inhibitor (dolutegravir) with a non-nucleoside reverse transcriptase inhibitor (rilpivirine). Dovato can be taken with or without food, but Juluca must be taken with a meal. Additionally, Dovato is not recommended for people with severe kidney or liver problems, while Juluca does not require dose adjustments for mild kidney or liver issues. Both medications can interact with other drugs, but Juluca specifically cannot be taken with proton pump inhibitors like omeprazole.
